SoteriaBio’s proprietary excipient BIORESPX™ stabilizes antibodies and other biologics for direct pulmonary delivery - unlocking local treatment, lower doses, and broader patient access.
Today’s biologics for respiratory diseases like asthma are delivered by injection, requiring high doses to reach the lungs and restricting their use to the most severe patient populations. This creates barriers to earlier treatment, reduces patient accessibility, and leaves life-cycle management potential untapped.
Inhaled delivery could significantly reduce required doses and broaden patient access significantly. The obstacle is formulation: aerosolization and nebulization expose antibodies to mechanical and chemical stresses that cause aggregation, loss of activity, and potential immunogenicity. No approved excipient addresses this for full-size monoclonal antibodies.
BIORESPX™ is a novel amphiphilic molecule (C16TreS) that stabilizes antibody structure during aerosolization and nebulization. Composed of clinically approved or physiologically present units, it enables direct pulmonary delivery of full-size monoclonal antibodies - a formulation challenge that has remained unsolved across the industry.
MOLECULAR ARCHITECTURE
Provides stability and biocompatibility during formulation and delivery
Natural sugar component offering enhanced structural integrity and physiological compatibility
Terminal group optimizing solubility and bioprocessing characteristics
The BIORESPX™ platform is designed to be compatible with a wide range of biologics and inhalation technologies. SoteriaBio is currently evaluating the platform across multiple antibodies and disease models to demonstrate its potential to enable inhaled biologic therapies for respiratory diseases.
Broad antibody compatibility
Compatible with a broad range of antibodies, validated using clinically approved antibodies.
Multiple inhalation technologies
Compatible with standard inhalation devices, with no need for custom hardware development.
Multiple disease indications
Applicable across multiple respiratory indications including asthma, infectious diseases, fibrosis and oncology.
Biocompatible & physiological
Built from clinically validated and physiologically relevant components, with a favorable safety and biodegradability profile.
If you are developing a monoclonal antibody or biological molecule for a respiratory indication, SoteriaBio can reformulate it for direct pulmonary delivery using our BIORESPX™ excipient platform—enabling inhaled administration across APIs and device technologies.
High drug concentration in the lungs
Lower off-target exposure
New value through inhalation delivery
SoteriaBio is advancing proof-of-concept studies in asthma, the largest market for respiratory biologics, to explore the potential of direct pulmonary delivery of antibodies. Our approach is designed to preserve antibody integrity under the stresses of nebulisation and enable effective deposition in the lungs, supporting local therapeutic activity.
Current standard of care relies on inhaled or oral corticosteroids and bronchodilators for symptom management, while only a limited number of biologics are approved for severe asthma. These therapies are administered systemically at high doses, often leading to side effects and restricted patient access, highlighting a significant unmet need for more targeted delivery approaches.
By shifting from systemic to localized delivery, it may offer improved safety profiles and expand the therapeutic window of existing and novel antibody-based treatments.
Limited biologic access
Only 2–3% of asthma patients currently progress to biologic therapies, despite a large unmet need
Systemic inefficiency
Less than 1% of systemically administered antibodies reach the lungs
Sever cases remain uncontrolled
Up to half of severe asthma patients remain uncontrolled despite available biologic therapies
SoteriaBio is a biotechnology company developing BIORESPX™, a proprietary excipient platform designed to enable the inhalation of biologics. By addressing the limitations of systemic antibody delivery, the company aims to unlock new therapeutic opportunities in respiratory diseases.
The team brings together expertise across biologics formulation, respiratory medicine, and drug development, combining scientific depth with entrepreneurial experience. SoteriaBio collaborates with the Institut Charles Gerhardt Montpellier (ICGM / CNRS) under the Companies & Campus program.
© 2026 SOTERIA BIO SAS — All rights reserved